A Trial of SHR1258 in Patients With Biliary Tract Cancer
The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers
Biliary Tract Cancer
DRUG: SHR1258
Objective response rate, Objective response rate (ORR) evaluated by Blinded Independent Radiology Review Committee (BIRC) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)., up to 2 years
DOR, Duration of response, up to 2 years|DCR, Disease Control Rate, up to 2 years|PFS, Progression-Free-Survival, up to 2 years|OS, overall survival, up to 2 years|AEs+SAEs, Adverse event, from the first drug administration to within 28 days for the last SHR1258 dose|Cmax, Peak Plasma Concentration, up to 2 years
The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers